Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia

Pediatric Blood and Cancer

Volumn 50, Issue 2, 2008, Pages 357-359

  Hines, Patrick ^a,b   Dover, George J ^a   Resar, Linda M S ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Hemoglobin F; Pulsed dosing; Sickle cell anemia; Sodium phenylbutyrate

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; HEMOGLOBIN F; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; DRUG DOSE INCREASE; DRUG EFFECT; DRUG PULSE THERAPY; DRUG SAFETY; HEMOGLOBIN DETERMINATION; HUMAN; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANEMIA, SICKLE CELL; CHILD; DRUG ADMINISTRATION SCHEDULE; FETAL HEMOGLOBIN; HUMANS; MALE; PHENYLBUTYRATES;

EID: 37549053288     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21104     Document Type: Article

References (18)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
2. Nagel RL, Bookchin RM, Johnson M, et al. Structural bases of the inhibitory effects of HbF and A2 on the polymerization of HbS. Proc Natl Acad Sci U S A 1979;76:670-672.
3. Bunn H. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762-769.
4. Platt OS, Orkin SH, Dover GJ, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984;74:652-656.
5. Charache S, Terrin ML, Moore RD, et al. Multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995;332:1317-1322.
6. Ferster A, Vermylen C, Cornu G, et al. Hydroxyuea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996;88:1960-1964.
7. Scott JP, Hillery CA, Brown ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996;128:820-828.
8. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97:3628-3632.
9. Ferster A, Sariban E, Meuleman N. Belgian registry of sickle cell disease patients treated with hydroxyurea. Malignancies in sickle cell disease patients treated with hydroxyurea. Br J Haematol 2003;123:368-379.
10. Maestri NE, Brusilow SW, Clissold DB, et al. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996;335:855-859.
11. Partington GA, Yarwood NJ, Rutherford TR. Human globin gene transcription in injected xenopus oocytes: Enhancement by sodium butyrate. Embo 1984;3:2787-2792.
12. Perrine SP, Rudolph A, Faller DV. Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. Proc Natl Acad Sci USA 1988;85:8540-8542.
13. Perrine SP, Miller BA, Faller DV, et al. Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with HbSS and thalassemia. Blood 1989;74:454-459.
14. Burns LJ, Glauber JG, Ginder GD. Butyrate induces selective transcriptional activation of a hypomethylated embryonic globin gene in adult erythroid cells. Blood 1988;72:1536-1542.
15. Stamatoyannopoulos G, Blau CA, Nakamato B, et al. Fetal hemoglobin induction by acetate, a product of butyrate catabolism. Blood 1994;84:3198.
16. Atweh GF, Sutton M, Nassif I. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999;93:1790-1797.
17. Resar LMS, Segal JB, Fitzpatric LK, et al. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. Am J Pediatr Hematol Oncol 2002;24:737-741.
18. Weinberg RS, Ji X, Sutton M, et al. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood 2005;105: 1807-1809.